These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3883600)

  • 1. Efficacy of a short course (four doses) of methotrexate following bone marrow transplantation for prevention of graft-versus-host disease.
    Smith BR; Parkman R; Lipton J; Nathan DG; Rappeport JM
    Transplantation; 1985 Mar; 39(3):326-9. PubMed ID: 3883600
    [No Abstract]   [Full Text] [Related]  

  • 2. Graft-versus-host disease.
    Gale RP
    Immunol Rev; 1985 Dec; 88():193-214. PubMed ID: 3910557
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
    Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J
    Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus with mini-methotrexate as prophylaxis for graft-versus-host disease in pediatric patients after allogeneic peripheral blood stem cell transplant or bone marrow transplant.
    Sabapathy C; Gourde JA; Khan SP; Rodriguez V
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):945-9. PubMed ID: 19131788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-host disease.
    Kodo H
    Nihon Ketsueki Gakkai Zasshi; 1987 Dec; 50(8):1621-6. PubMed ID: 2833846
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of immunosuppressive drugs for prevention of graft-v-host disease after bone marrow transplantation.
    Devergie A; Esperou H; Traineau R; Varrin F; Lehn P; Gluckman E
    Nouv Rev Fr Hematol (1978); 1989; 31(2):73-5. PubMed ID: 2671932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bone marrow transplantation for therapy of leukemia].
    Masaoka T
    Nihon Naika Gakkai Zasshi; 1992 Jul; 81(7):1060-4. PubMed ID: 1383366
    [No Abstract]   [Full Text] [Related]  

  • 11. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Beelen DW; Quabeck K; Kaiser B; Wiefelspütz J; Scheulen ME; Graeven U; Grosse-Wilde H; Sayer HG; Schaefer UW
    Transplantation; 1990 Sep; 50(3):421-7. PubMed ID: 2402791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified methotrexate regimen for prevention of graft-versus-host disease.
    Vowels M; Lam-Po-Tang R; Mameghan H; Ford D; Hughes DO
    Transplant Proc; 1986 Apr; 18(2):276-7. PubMed ID: 3515665
    [No Abstract]   [Full Text] [Related]  

  • 13. Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors.
    Weiner RS; Bortin MM; Gale RP; Gluckman E; Kay HE; Kolb HJ; Hartz AJ; Rimm AA
    Ann Intern Med; 1986 Feb; 104(2):168-75. PubMed ID: 3511812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM
    N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to graft-versus-host disease following bone marrow transplantation in monkeys and man.
    Dicke KA; Spitzer G; Peters L; Stevens EE; Hendriks W; McCredie tkb
    Transplant Proc; 1978 Mar; 10(1):217-21. PubMed ID: 416529
    [No Abstract]   [Full Text] [Related]  

  • 17. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation.
    Yu C; Storb R; Deeg HJ; Graham TC; Scheuning FG; Huss R; Seidel K; Fitzsimmons WE
    Bone Marrow Transplant; 1996 Apr; 17(4):649-53. PubMed ID: 8722370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of immunosuppressive drugs for prevention of graft-v-host disease after human HLA matched bone marrow transplantation.
    Gluckman E; Devergie A; Lokiec F; Traineau R; Cosset JM; Lemercier N; Varrin F; Cavazzana M; de Castro H; Meletis J
    Transplant Proc; 1987 Dec; 19(6 Suppl 7):61-5. PubMed ID: 3321648
    [No Abstract]   [Full Text] [Related]  

  • 19. Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents.
    Remberger M; Ringdén O
    Transplantation; 2007 Aug; 84(4):551-4. PubMed ID: 17713443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.